课题基金 / 基金详情

项目摘要

项目成果

Charles E Egwuagu的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
One of our objectives in this study was to investigate whether the aberrant upregulation of cytokine secretion in patients with persistent ocular inflammatory disease derives in part from defects in proteins that mediate negative feedback regulation of activities of proinflammatory cytokine. We found that PBMC of patients with scleritis could not induce the expression of the negative feedback regulatory protein SOCS1. Because ethical considerations and NIH IRB guidelines precluded obtaining retinal tissue biopsy to determine whether SOCS expression is also defective in ocular tissues of scleritis patients, we generated transgenic mice and rats with over-expression of SOCS1 in the retina and used these animals to further investigate the role of SOCS1 in the retina and intraocular inflammatory diseases. Although results from several studies suggest that induction of SOCS1, SOCS3 and CIS by inflammatory cells mitigates immune responses by regulating the intensity and duration of cytokine signals, until now it has not been clear whether retinal cells also produce SOCS1 and what physiological role they might have during ocular inflammation. By targeting the over-expression of SOCS1 to the retina of rats and mice and examining the in vivo function of SOCS1 in the well-characterized EAU model, we show that SOCS1 protects mice and rats from developing severe uveitis. Our data suggests that proinflammatory cytokines produced during EAU induces retinal cells to repress the production of chemotactic cytokines and this results in substantial decrease in the numbers of pathogenic T cells recruited into the retina during uveitis. Defective expression of SOCS1 in patients with scleritis, taken together with our data showing that SOCS1 mediated protection of neuroretinal cells from apoptosis, suggests that SOCS1 has neuroprotective function in the retina and imply that administration of SOCS1 mimetic peptides maybe useful in treating uveitis or scleritis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interferon-inducible Transcription Factors: Roles In Ocu
  • 批准号:
    6507394
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Charles E Egwuagu
  • 依托单位:
INTERFERON INDUCIBLE TRANSCRIPTION FACTORS: ROLES IN OCU
  • 批准号:
    6414669
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Charles E Egwuagu
  • 依托单位:
Development of dendritic cell vaccine against uveitis
  • 批准号:
    6968529
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Charles E Egwuagu
  • 依托单位:
Development of dendritic cell vaccine against uveitis
  • 批准号:
    7139194
  • 项目类别:
  • 资助金额:
    $0.0万
  • 财政年份:
    --
  • 负责人:
    Charles E Egwuagu
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: